Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

152.64 2.07 −1.34%
Market cap
$17.3B
P/E
72.7×
Fwd P/E
37.5×
Dividend yield
0.23%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

44.05 46.51 41.92 52.98
P/S ratio
3.60 3.95 3.38 4.26
P/FCF ratio
20.54 22.35 19.73 21.97
P/Operating CF
73.04 61.97 85.04 64.68
P/B ratio
1.37 1.56 1.36 1.72
EV/Sales
4.41 4.75 4.19 5.01
EV/EBITDA
15.99 17.71 15.62 18.82
EV/FCF
25.18 26.91 24.46 25.83
Current Ratio
1.75 1.68 1.72 1.80
Net Debt/EBITDA
12.33 10.66 12.89 11.33
Debt/Equity
0.44 0.44 0.45 0.44
Earnings Yield
2.27% 2.15% 2.39% 1.89%
Free Cash Flow Yield
4.87% 4.47% 5.07% 4.55%
Free Cash Flow per Share
1.04 1.39 0.93 1.65
Book value per Share
63.91 62.21 64.22 64.78
Free Cash Flow
120.00 161.79 104.46 183.91
EV/EBIT
34.10 38.07 33.71 40.68
Other line items

Show all line items

Columns are period end dates